PROVENGE Significantly Prolongs Survival in Men with Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

What great news has greeted us today. We can now hope that the FDA will quickly approve Provenge and we can get this sorely needed treatment ASAP. If Provenge gets approval from the FDA it will be the first cancer vaccine ever approved. Sadly it will be only the second approved treatment for prostate cancer!

If you search for Provenge in this blog you can learn about the battles to date to obtain approval and how the treatment works.

–Joel T Nowak MA, MSW

Dendreon Corporation

PROVENGE Significantly Prolongs Survival in Men with Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

– Study Meets Primary Endpoint Showing Statistically Significant Improvement in Overall Survival –
– First Active Immunotherapy for Cancer to Prolong Survival –
– Full Data to be Presented at Plenary Session at Upcoming AUA Annual Meeting –
– Company to Host a Conference Call Today at 9:00 AM ET –

SEATTLE, April 14, 2009 – Dendreon Corporation (Nasdaq: DNDN) announced today that the pivotal Phase 3 IMPACT study of PROVENGE® (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of improving overall survi